KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer.

Zhiwei Chen, Jianhua Chen, Dingzhi Huang, Wei Zhang, Lin Wu, Tienan Yi, Qiming Wang, Liang Han, Liping Tan, Yinyin Li, Zhihong Zhang, Na Li, Jie Li, Tongmei Zhang, Ying Hu, Hongmei Sun, Youhua Wu, Zhiyong He, Runxiang Yang, Peng Cheng, Xingya Li, Jianhua Shi, Guohua Yu, Daiyuan Ma, Benjamin Xiaoyi Li, Xiangrong Dai, Michael Wong, Yujie Li, Xiaohui Yu, Shun Lu, Socazolimab Study Group

Signal Transduct Target Ther 10(1) 28

PMID39800716
PMCIDPMC11725569
DOI10.1038/s41392-024-02115-5
发表日期2025-01-12
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

This is a randomized, double-blind, placebo-controlled phase 3 clinical trial (ClinicalTrials.gov, NCT04878016) conducted in 54 hospitals in China. Adults who were histologically diagnosed and never treated for extensive-stage small cell lung cancer (ES-SCLC) were enrolled. Eligible Patients were randomly assigned (1:1) to receive four cycles (21 days as one cycle) of intravenous carboplatin (area under the curve of 5 mg/mL per min, day 1 of each cycle) and etoposide (100 mg/m² of body-surface area, on days 1-3 of each cycle) with either socazolimab (5 mg/kg, day 1 of each cycle) or matching placebo, following maintenance therapy with socazolimab or placebo. From July 15, 2021, to May 12, 2022, 498 eligible patients were randomly assigned to receive socazolimab (250 patients) or placebo (248 patients) combined with chemotherapy. As of October 13, 2023, patients treated with socazolimab presented significant overall survival (OS) benefit (13.90 months) compared with the placebo plus EC group (11.58 months) (hazard ratio for death, 0.799; 95% CI, 0.652-0.979; p = 0.0158). The median progression free survival (PFS) was 5.55 months in the socazolimab plus EC group, prolonging disease progression or death by nearly 1.2 months (5.55 months vs 4.37 months, hazard ratio for progression or death, 0.569; 95% CI, 0.457-0.708; p < 0.0001). 200 (80.3%) patients in the socazolimab plus EC group experienced ≥ grade 3 treatment-related adverse events and 187 (75.7%) patients occurred in the placebo plus EC group. Socazolimab combined with standard EC regimen chemotherapy for first-line treatment of ES-SCLC significantly prolonged overall survival and did not increase the safety risk of treatment.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 2

Fig. 2 a Kaplan-Meier curve of overall survival. b Forest plot of subgroup analysis of overall survival Median OS follow-up time was estimated by the reverse Kaplan-Meier method with 95% Cis estimated using the Brookmeyer-Crowley method. The median duration of follow-up for overall survival was 20.47 months (IQR, 18.33–22.18 months) for the socazolimab plus EC group and 20.63 months (IQR, 19.78–21.49 months) for the placebo plus EC group. * Calculated using a 2-sided stratified log-rank test

A

overall survival

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
KM Figure1 个面板

Fig. 3

Fig. 3 a Kaplan-Meier curve of progression free survival. b Forest plot of subgroup analysis of progression free survival. Data are from assessments by the independent radiology review committee using RECIST version 1.1. The median duration of follow-up for progression-free survival was 13.6months (IQR, 4.67–18.37 months) for the socazolimab plus EC group and 16.62 months (IQR, 5.09–18.07 months) for the placebo plus EC group. * Calculated using a 2-sided stratified log-rank test

A

PFS

Fig. 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Trial Profile. The date of data cutoff was October 13, 2023. * The maximum duration of treatment allowed for socazolimab or placebo was 2 years. One patient discontinued treatment due to reaching the maximum medication duration of 2 years. # full analysis: all Patients who received at least 1 dose of study treatment
非 KM Figure